News

The product will be launched under the name Junel Fe 24 (norethindrone acetate and ethinyl estradiol tablets USP and ferrous fumarate tablets) and is currently available in the

MM-398 is a new, stable nanotherapeutic encapsulation of the marketed chemotherapy drug irinotecan. The filing follows the recent submissions of NDA and marketing authorization application (MAA) by its

The trial is designed to evaluate the benefit of Kyprolis administered once-weekly with dexamethasone versus the current FDA-approved twice-weekly administration schedule in patients who have received prior treatment

PARP, or poly (ADP-ribose) polymerase, is a DNA repair protein that restores single strand DNA breaks and by inhibiting PARP, certain cancer cells may be rendered unable to

The trial will evaluate the safety and preliminary efficacy of AstraZeneca’s investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Lilly’s vascular endothelial growth factor (VEGF) Receptor 2

Cerdulatinib is an oral, dual Syk-JAK kinase inhibitor that Portola is developing to treat patients with hematologic cancers, specifically those who have relapsed or who have not responded

Argatroban Injection is an anticoagulant indicated for prophylaxis or treatment of thrombosis in adult patients with heparin induced thrombocytopenia (HIT), or as an anticoagulant in adult patients with

Results from the Phase 3 PALOMA-3 study will be featured today in a press briefing during the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO)

The data included in the MAA support the use of F/TAF to treat HIV-1 infection in adults in combination with other HIV antiretroviral agents. TAF is a new